Neumora Therapeutics (NMRA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic vision and pipeline overview

• Focused on developing novel therapies for prevalent brain diseases, leveraging an industry-leading CNS pipeline with seven candidates and long IP protection.

• Maintains a strong balance sheet, having raised over $850 million, providing financial flexibility to adapt and fund ongoing programs.

• Pipeline includes both neurodegenerative and neuropsychiatric disease programs, with global rights to all assets.

• Multiple clinical catalysts expected in the coming year, supporting value creation for patients and investors.

• Emphasizes a world-class team and data-driven approach to drug development.

Navacaprant clinical development and learnings

• KOASTAL-1 phase III trial for depression did not meet primary or key secondary endpoints but showed encouraging trends, especially in female patients.

• Higher placebo response observed in males, with consistent benefit trends in females across efficacy measures.

• Safety and tolerability profile remains favorable, with no serious adverse events and balanced discontinuation rates.

• Ongoing analyses aim to understand sex differences and placebo effects, with modifications planned for KOASTAL-2 and KOASTAL-3 studies.

• Bipolar II depression study is signal-seeking, focusing on totality of data to inform next steps and potential expansion.

Broader pipeline and future catalysts

• NMRA-511, a vasopressin 1a receptor antagonist, is in phase Ib for Alzheimer's agitation, with data expected in the second half of the year.

• Muscarinic M4 modulator program advancing, with plans to bring a new asset into the clinic in the first half of the year.

• Preclinical pipeline includes four programs targeting diseases like Parkinson's, Alzheimer's, and ALS, with strong biological and genetic rationale.

• Diversified portfolio strategy supports multiple value creation opportunities across indications and stages.

• Financial position is strong, with cash runway into mid-2026, supporting ongoing and future development.